Haemonetics to acquire OpSens for $2.90/share cash via arrangement

HAEMONETICS CORP

Haemonetics to acquire all outstanding shares of OpSens via plan of arrangement under Quebec Business Corporations Act.
Consideration of $2.90 per share in cash; termination fee of $12.075 million payable by OpSens in certain circumstances.
Support and voting agreements with certain shareholders to vote in favor of the arrangement resolution.
Transaction subject to shareholder approval, Quebec Superior Court order, and regulatory clearances.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.